Long-Term Anticoagulation for Patients Receiving Dialysis

Sagar U Nigwekar¹, Ravi Thadhani^{1

2}

Affiliations

¹ Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston (S.U.N., R.T.).
² Department of Biomedical Sciences and Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA (R.T.).

Editorial

Sagar U Nigwekar et al. Circulation. 2018.

. 2018 Oct 9;138(15):1530-1533.

doi: 10.1161/CIRCULATIONAHA.118.037091.

Sagar U Nigwekar¹, Ravi Thadhani^{1

2}

¹ Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston (S.U.N., R.T.).
² Department of Biomedical Sciences and Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA (R.T.).

No abstract available

Keywords: Editorials; apixaban; calciphylaxis; dialysis; kidney failure, chronic; vascular calcification; vitamin K; warfarin.

Comment on

Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States.
Siontis KC, Zhang X, Eckard A, Bhave N, Schaubel DE, He K, Tilea A, Stack AG, Balkrishnan R, Yao X, Noseworthy PA, Shah ND, Saran R, Nallamothu BK. Siontis KC, et al. Circulation. 2018 Oct 9;138(15):1519-1529. doi: 10.1161/CIRCULATIONAHA.118.035418. Circulation. 2018. PMID: 29954737 Free PMC article.